Darinaparsin Is a Multivalent Chemotherapeutic Which Induces Incomplete Stress Response with Disruption of Microtubules and Shh Signaling by Mason, Twila A. et al.
Darinaparsin Is a Multivalent Chemotherapeutic Which
Induces Incomplete Stress Response with Disruption of
Microtubules and Shh Signaling
Twila A. Mason
1,2, Elena Kolobova
2,3, Jiang Liu
1, Joseph T. Roland
2,3, Chin Chiang
1, James R.
Goldenring
1,2,3*
1Department of Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, 2Epithelial Biology Center,
Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, 3Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee,
United States of America
Abstract
Chemotherapeutics and other pharmaceuticals are common sources of cellular stress. Darinaparsin (ZIO-101) is a novel
organic arsenical under evaluation as a cancer chemotherapeutic, but the drug’s precise mechanism of action is unclear.
Stress granule formation is an important cellular stress response, but the mechanisms of formation, maintenance, and
dispersal of RNA-containing granules are not fully understood. During stress, small, diffuse granules initially form
throughout the cytoplasm. These granules then coalesce near the nucleus into larger granules that disperse once the
cellular stress is removed. Complete stress granule formation is dependent upon microtubules. Human cervical cancer
(HeLa) cells, pre-treated with nocodazole for microtubule depolymerization, formed only small, diffuse stress granules upon
sodium arsenite treatment. Darinaparsin, as a single agent, also induced the formation of small, diffuse stress granules, an
effect similar to that of the combination of nocodazole with sodium arsenite. Darinaparsin inhibited the polymerization of
microtubules both in vivo and in vitro. Interestingly, upon removal of darinaparsin, the small, diffuse stress granules
completed formation with coalescence in the perinuclear region prior to disassembly. These results indicate that RNA stress
granules must complete formation prior to disassembly, and completion of stress granule formation is dependent upon
microtubules. Finally, treatment of cells with darinaparsin led to a reduction in Sonic hedgehog (Shh) stimulated activation
of Gli1 and a loss of primary cilia. Therefore, darinaparsin represents a unique multivalent chemotherapeutic acting on stress
induction, microtubule polymerization, and Shh signaling.
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Introduction
All cells experience various stressors during their physiological
processes. Stress is a ubiquitous problem and can trigger a range of
responses within cells. Common stressors include heat shock,
oxidative conditions, viral infection, hypoxia, mitochondrial stress,
DNA-damaging agents, and ultraviolet irradiation [1,2]. Chemo-
therapeutic drugs and other pharmaceuticals are other common
sources of cellular stress.
Arsenicals are one category of chemotherapeutics undergoing
continual investigation. Organic and inorganic arsenicals have
been used in the treatment of disease for thousands of years [3,4].
However, arsenicals are typically very potent and their toxicity
typically limits their use [4,5]. Currently, arsenic trioxide (ATO,
As2O3), an inorganic arsenical, is used for treatment in cases of
recurrent acute promyelocytic leukemia [6]. This drug is limited
by its toxicity on the liver and cardiovascular system. Because of
these toxicity issues, the development of less toxic arsenicals has
become an area of great interest.
Darinaparsin (ZIO-101, S-dimethylarsino-glutathione) is an
organic arsenical that is currently in Phase II clinical trials as a
chemotherapeutic agent [5,7]. While darinaparsin shows clinical
promise, the drug’s mechanism of action continues to be
investigated. A series of in vitro and in vivo studies, coupled with
observed differences in toxicity and potency, suggest darinaparsin
employs a mechanism of action that is different from that of ATO.
Darinaparsin appears more potent than ATO as some ATO-
resistant cells are sensitive to the drug. Moreover, other cell types
have shown an increased sensitivity to darinaparsin compared to
ATO. [5,6,8,9]. Importantly darinaparsin does not demonstrate
the same level or type of toxicity as ATO with no apparent toxicity
to the liver or cardiovascular system.
Previous studies have shown that both ATO and darinaparsin
cause apoptosis and cell cycle arrest at G2/M in tumor cells [4,6].
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27699This effect is thought to occur in part through the disruption of
mitochondrial functions, which leads to increased production of
reactive oxygen species (ROS) [10]. An increase in ROS, if great
enough, can trigger a cellular stress response. Recent preclinical
studies of darinaparsin have shown anti-angiogenic activity in vitro
and in vivo through controlling several signal transduction
pathways [6] and that darinaparsin is more potent than ATO
under hypoxic conditions [11].
One critical mechanism in the cellular stress response is the
formation of RNA stress granules. Stress granules function to
sequester mRNAs and proteins during cellular stress. Importantly,
stress granules are not stable structures, but are dynamic with a
constant flux of proteins and mRNAs. Stress granules are generally
composed of a variety of preinitiation- and translation-related
factors, proteins linked to mRNA metabolism, mRNAs, and RNA-
binding proteins, as well as signaling proteins with no known link
to mRNA [2]. Typically, proteins and mRNAs necessary for cell
survival during stress, such as heat shock proteins, are not
sequestered in stress granules. The mRNAs are sequestered in
stress granules until the cell is no longer stressed or undergoes
apoptosis [12]. Once stress is no longer present, stress granules
disperse, and the sequestered mRNAs can be translated. Other
RNA granules also exist in cells without stress, such as processing
bodies (P-bodies) [1]. The different RNA granules do contain
unique components, with stress granules containing components
specialized for adaptation to dynamic stressors. Though stress
granule formation appears to be a ubiquitous cellular response, the
mechanisms regulating formation, maintenance, and dispersal
remain largely obscure.
In this study, we examined both the mechanism of action for
darinaparsin and the dynamics of stress granules formation,
maintenance, and dispersal. We propose that darinaparsin is a
potent chemotherapeutic because it initiates a stress response,
while also stalling the completion of the stress response by
simultaneously depolymerizing microtubules. The depolymeriza-
tion of microtubules causes the stress granules to form incom-
pletely, preventing the coalescence of stress granule components.
When darinaparsin is withdrawn, stress granules progress to final
coalescence as microtubules repolymerize and disperse only after
complete granule formation. In addition, likely due to microtubule
depolymerization, darinaparsin causes a loss of primary cilia and a
reduction in Shh signaling. These findings support the concept
that darinaparsin is a multivalent chemotherapeutic affecting
several critical processes in neoplastic cells.
Results
Darinaparsin and sodium arsenite induce stress granule
formation
Since darinaparsin is an organic arsenical, we first sought to
evaluate whether darinaparsin could elicit RNA stress granules.
To determine the effect of darinaparsin on cells, we treated cells
with darinaparsin and compared its effects to those of sodium
arsenite. Treatment of HeLa cells with 0.05 mM darinaparsin for
30 minutes induced stress granule formation, detected with
antibodies against G3BP (Figure 1). A titration of darinaparsin
for short incubations showed stress granule formation was induced
in a majority of cells at 0.03 mM. Sodium arsenite treatment at
0.5 mM induced stress granule formation, as previously reported
[1,2]. Nevertheless, the stress granules induced by darinaparsin
appeared smaller and were significantly greater in number when
compared to sodium arsenite-induced stress granules, and the
granules were more dispersed throughout the cytoplasm
(Figure 1E).
As noted above, stress granule formation is a dynamic
process. Upon initial stress granule induction, many small
granules form throughout the cytoplasm. As stress continues, the
smaller granules coalesce near the nucleus to form large,
complete stress granules [1]. The large, complete stress granules
generally have similar compositions, but the smaller granules
can vary in composition [1]. Because stress granules can vary in
composition, we evaluated the stress granules induced by
darinaparsin in HeLa cells compared with stress granules
induced by sodium arsenite, and cells that received no treatment
served as a control (Figure 1). We first studied the association of
markers of Processing bodies (P bodies) with induced stress
granules. P-bodies serve as RNA degradation centers and are
present in the absence or presence of cellular stress [2,13]. Stress
granules and P-bodies are separate entities, but they do
communicate with one another and are dynamically linked
[14]. To ensure the granules induced by darinaparsin were not
P-bodies, we compared staining of a P-body marker, GW182,
and a stress granule marker, G3BP (Figure 1A). In untreated
cells, GW182-stained P-bodies were small and distributed
throughout the cytoplasm, while G3BP was diffuse throughout
the cytosol. Sodium arsenite treatment induced large G3BP-
staining stress granules that clustered in the perinuclear region.
Only a few of the larger stress granules showed dual
immunostaining with both G3BP and GW182. Similarly, there
was little overlap between the smaller darinaparsin-induced
granules and GW182-labelled P-bodies.
We next examined the presence of proteins previously found in
stress granules in the granules induced by darinaparsin.
AKAP350A, a large scaffolding protein, localizes to stress granules
and is important for their complete formation [1]. Knockdown of
AKAP350A with siRNA results in smaller stress granules upon
treatment with sodium arsenite. AKAP350A colocalized with
G3BP in stress granules induced by sodium arsenite (Figure 1B).
After darinaparsin treatment, some granules contained both
AKAP350A and G3BP, while others contained only one of the
components. Granules containing only one component were
typically smaller and in the periphery of the cytoplasm.
AKAP350A interacts with RNA-binding proteins Caprin-1 and
CCAR1, both of which are also present in stress granules
[1,15,16]. Caprin-1 colocalized with G3BP in stress granules
induced by both sodium arsenite and darinaparsin (Figure 1C).
CCAR1 and G3BP colocalized in stress granules induced by
sodium arsenite (Figure 1D). However, as with AKAP350A, in
darinaparsin-treated cells some stress granules contain both
CCAR1 and G3BP, but many smaller granules stained for only
one of the components.
Darinaparsin inhibits microtubule polymerization
In previous studies, we have shown that microtubules are
necessary for complete stress granule formation [1]. Pre-treatment
of cells with nocodazole, which inhibits microtubule polymeriza-
tion, prior to treatment with sodium arsenite, leads to the
formation of stress granules which are smaller and greater in
number. The smaller granules suggest incomplete stress granule
formation. The similarity between darinaparsin-induced and
nocodazole/sodium arsenite-induced stress granules led us to
hypothesize that darinaparsin induces incomplete stress granule
formation due to microtubule depolymerization. Immunofluores-
cence in HeLa cells demonstrated that treatment with darina-
parsin did induce microtubule depolymerization along with
inducing stress granule formation (Figure 2A). In cells treated
with darinaparsin, microtubules were almost completely depoly-
merized, showing mainly cytosolic alpha-tubulin staining. In
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microtubules.
To verify the effects of darinaparsin on microtubules, we
assessed in vitro microtubule polymerization (Figure 2B). Darina-
parsin inhibited GTP-stimulated microtubule polymerization in a
concentration-dependent manner. Darinaparsin also inhibited
polymerization of microtubules stimulated by taxol, a microtubule
stabilizer, at similar concentrations (data not shown). These results
suggest that darinaparsin sequesters free tubulin monomers,
similar to the action of nocodazole [17]. In contrast, sodium
arsenite had only minimal effect on microtubule polymerization at
concentrations up to 1 mM. Importantly, darinaparsin had no
Figure 1. Darinaparsin and sodium arsenite induce RNA stress granules. HeLa cells were treated with 0.5 mM Sodium arsenite or 0.05 mM
darinaparsin for 45 minutes at 37uC. Cells were fixed with supplemented 4% PFA. All cells are stained for DNA with Dapi (blue) and A. G3BP (green)
and GW-182 (red), B. AKAP350 (green) and G3BP (red), C. Caprin-1 (green) and G3BP (red), D. CCAR1 (green) and G3BP (red). E. The number of
granules in sodium arsenite- and darinaparsin-treated cells was quantified using ImageJ software. Results are mean +/2 standard error. *p,0.0001
(Scale bars: 20 mM).
doi:10.1371/journal.pone.0027699.g001
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(data not shown).
Stress granules must complete formation before
dispersal
We have previously shown that stress granules initially form as
small granules in the cytosol, that then coalesce into the final,
complete stress granules in the perinuclear region [1]. We now
sought to evaluate stress granule dynamics further by investigating
their dispersal once stress is relieved. Because darinaparsin, sodium
arsenite, and nocodazole/sodium arsenite have differing effects,
we monitored the dynamics of stress granule formation and
dispersal during each treatment.
We assessed the course of recovery of HeLa cells after treatment
with 0.05 mM darinaparsin, 0.5 mM sodium arsenite, or a
combination of 33 nM nocodazole and 0.5 mM sodium arsenite.
Cells were fixed at the end of treatment for 45 minutes and after
periods of recovery without treatment for up to three hours in
complete media (Figure 3). At the end of treatment, sodium
arsenite-treated cells had large, complete stress granules and intact
microtubules, as expected (Figure 3). After recovering without
drug for one hour, the sodium arsenite-treated cells showed fewer
stress granules, and by two hours of recovery, the stress granules
had completely dispersed into the cytoplasm. The microtubules
remained unaffected by the sodium arsenite treatment for the
duration of the experiment.
In cells treated with darinaparsin, the microtubules were
depolymerized and stress granules were significantly smaller than
sodium arsenite-induced stress granules at the end of treatment
(Figure 3). After one hour of recovery in the absence of drug, the
microtubules in cells treated with darinaparsin were repolymer-
ized, and larger stress granules were now observed, especially in
the perinuclear region. After three hours of recovery, darinaparsin
treated cells fully recovered with dispersal of stress granules.
Similar results were obtained in recovery from the combination of
treatment with both nocodazole and sodium arsenite, but recovery
occurred more slowly (data not shown). The dynamics of stress
granule formation are more clearly seen in continuous live cell
imaging. Movie S1 demonstrates that, following removal of
darinaparsin, small G3BP-labeled stress granules first coalesced
in the perinuclear region and then dispersed. These results suggest
that stress granules must complete formation by coalescence along
microtubule-dependent tracks before they can disperse into the
cytoplasm.
Darinaparsin affects Sonic Hedgehog signaling
Recent investigations have reported that ATO inhibits hedge-
hog signaling [18,19]. We sought to investigate whether
darinaparsin also affects hedgehog signaling. Previous studies have
shown that ATO does not affect primary cilium formation in
mouse embryonic fibroblasts (MEFs) [18]. To test the effects of
darinaparsin on primary cilia, NIH 3T3 cells were grown and
induced to form primary cilia. The cells were treated with 100 nM
Smoothened Agonist (SAG) with or without 600 nM or 1 mM
darinaparsin for 24 hours [20]. The concentration of darinaparsin
needed for long incubations was titrated, and 600 nM was the
optimal concentration to have an effect while not causing cell
death. Fixed cells were stained for Arl13b to mark primary cilia.
Unlike cells treated with ATO, cells treated with 600 nM
darinaparsin had a significant decrease in the number of primary
cilia. There was further loss of primary cilia at 1 mM darinaparsin,
suggesting a concentration-dependent decrease in primary cilia
Figure 2. Darinaparsin inhibits microtubule polymerization. A. HeLa cells were treated with 0.5 mM Sodium arsenite or 0.05 mM
darinaparsin, or 33 nM Nocodazole/0.5 mM Sodium arsenite. Cells are stained for DNA (Dapi, blue), a-tubulin (red), and Caprin-1 (green; stress granule
marker). GTP-initiation microtubule polymerization in the presence of darinaparsin (B) and sodium arsenite (C) was measured in vitro. (Scale bars:
20 mM).
doi:10.1371/journal.pone.0027699.g002
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PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27699Figure 3. Stress granules must complete formation before dispersal. HeLa cells were treated with 0.5 mM Sodium arsenite or 0.05 mM
darinaparsin. The 0 hour timepoint was taken at the end of treatment. For recovery, cells were incubated in complete RPMI media. Cells were fixed at
timepoints with supplemented 4% PFA and stained for Caprin-1 and a-tubulin (A). B. Granule size was quantified for each hour of recovery using
ImageJ software. There were no granules at 2 hours of recovery from sodium arsenite. Results are mean +/2 standard error. +p,0.0001 vs. sodium
arsenite-treated. *p,0.0001 vs. darinaparsin 0 hours of recovery. **p,0.0001 vs. darinaparsin 1 hour of recovery. (Scale bars: 20 mM).
doi:10.1371/journal.pone.0027699.g003
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PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27699(Figure 4). In darinaparsin-treated cells that did form primary cilia,
the primary cilia were shorter in length. Similar to ATO [18],
darinaparsin treatment did not alter the intracellular localization
of Gli1 (data not shown). Given the loss of primary cilia observed
with darinaparsin treatment, we also evaluated the drug’s effect on
Shh signaling through an assay of Gli1 activation. Figure 4
demonstrates that darinaparsin elicited a concentration-dependent
inhibition of Shh signaling, as seen with ATO [19]. These results
indicate that darinaparsin has broad effects on stress granule
formation, microtubule dynamics and Shh signaling.
Darinaparsin effects are independent of Mdr1 expression
Darinaparsin is a multivalent drug that appears to be more
potent than similar drugs, such as ATO. Therefore, we tested its
efficacy in cells with multiple drug resistance. Multiple drug
resistance transporters are often a limiting factor on the practical
efficacy of chemotherapeutic agents, especially in recurrent
cancers [21]. While ATO is used to treat hematological
malignancies, its use is limited in cancers expressing the multiple
drug resistance protein, MRP-1 [8]. MRP1-expressing cells are
resistant to ATO treatment, but are sensitive to treatment with
darinaparsin [8]. This prompted us to examine another major
drug resistance protein, Mdr1, which can rapidly pump drugs out
of resistant cancer cells. Previous investigations have shown that
ATO is not a substrate for Mdr1, and thus is effective in Mdr1-
expressing cells [21]. We evaluated the effects of darinaparsin on
stress granule formation in uterine sarcoma cells lines with or
without expression of Mdr1. Figure 5 demonstrates that
darinaparsin and sodium arsenite induced stress granules in both
ME-SA cells, which do not express Mdr1, and ME-SA/Dx5 cells,
which strongly over-express Mdr1. Indeed, the Mdr1-over-
expressing cells appeared to be more susceptible to darinaparsin
treatment as shown by the rapid rounding up of these cells after
treatment. Along with previous studies, these results demonstrate
that darinaparsin effects are not altered by expression of multiple-
drug resistance transporters.
Discussion
Arsenic salts are one of the oldest pharmaceutical classes [3].
Treatment with arsenicals has been utilized for both infectious
diseases and cancer. While ATO is approved for treatment of
refractory leukemias, its toxicity limits its use [6]. In contrast,
darinaparsin, an organic arsenical, shows a wide range of potency
against many cancer cells and has low toxicity when administered
in humans [6]. While darinaparsin induces apoptosis and G2/M
arrest in a number of cell lines, the exact mechanism responsible
for the anti-neoplastic effects of the compound seem to vary
according to cell types [6]. The present investigation indicates
that darinaparsin acts as a multivalent pharmaceutical that
induces a stress response, but does not permit its completion due
to its influence as a microtubule polymerization inhibitor.
Microtubule depolymerization by darinaparsin also causes loss
of primary cilia and Shh signaling, likely due to a loss of
Smoothened presentation. Inhibition of microtubule polymeriza-
tion by darinaparsin likely accounts for the arrest of cells in G2/
M noted in previous studies [6]. The G2/M arrest is
characteristic of microtubule depolymerization inhibitors such
as nocodazole [22]. Together these effects make this organic
arsenical drug a potent chemotherapeutic with multiple mecha-
nisms that target key regulators of neoplasia.
Formation of RNA stress granules following various cellular
stressors is considered a critical adaptive mechanism in cell
survival. Stress granules accumulate translational intermediates
including critical mRNAs that are important for reestablishment
of cell function after the release of stress [2]. Darinaparsin
induces stress granule formation and simultaneously inhibits
microtubule polymerization. This scenario leads to incomplete
formation of stress granules. The inability to form stress granules
or incomplete stress granule formation likely leads to apoptosis in
affected cells [12]. Importantly, the unique property of darina-
parsin to stimulate incomplete stress granule formation has
allowed us to investigate the process of stress granule processing
after removal of the blockade. Removal of darinaparsin led to
Figure 4. Darinaparsin inhibits Sonic Hedgehog signaling and primary cilia formation. NIH 3T3 fibroblasts were treated with 1001 nM
SAG (Shh agonist) with or without 0.6 mMo r1mM darinaparsin (ZIO-101). A. Cells were fixed with 4% PFA and stained for DNA (Dapi; blue), primary
cilia (Arl13b; green), and a-tubulin (red). B. The number of primary cilia was determined from 6 samples per genotype (15–30 cells per sample). C. The
length of primary cilia was determined using Image J software. P values were calculated using unpaired t-test with n–1 degree of freedom
(GraphPad). **p,0.005, ***p,0.0001. D. Luciferase assays were performed in the absence or presence of darinaparsin. (Scale bars: 20 mM).
doi:10.1371/journal.pone.0027699.g004
Figure 5. Darinaparsin is effective in Mdr-1-expressing cells.
ME-SA and ME-SA/Dx5 cells were untreated or treated with 0.5 mM
Sodium arsenite or 0.05 mM darinaparsin for 30 minutes at 37uC. Cells
were fixed with supplemented 4% PFA and stained for G3BP.
doi:10.1371/journal.pone.0027699.g005
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smaller granules into larger perinuclear granules, coincident with
the repolymerization of microtubules. These results are consistent
with our previous results that stress granules form initially in the
cell periphery and then coalesce after centripetal transport along
microtubule tracks [1]. Following withdrawal of darinaparsin,
stress granules only dissipated after completion of granule
formation. These findings indicate that stress granules must
complete their full program of formation and coalescence prior to
subsequent disassembly.
Recent investigations have noted that arsenic trioxide can
inhibit Shh signaling [18,19]. Similarly, we have observed that
darinaparsin also strongly inhibits Shh-induced Gli1 expression.
Nevertheless, in contrast with arsenic trioxide, darinaparsin also
causes the loss of microtubules and the primary cilium, the site of
Smoothened presentation [18,19]. Since Shh is considered a major
driver in multiple cancers, it appears that darinaparsin has the
ability to dismantle key aspects of Shh signaling machinery
necessary for the proliferative drive in neoplastic cells.
Darinaparsin appears to be more potent but less toxic than
ATO. Previous studies have noted that darinaparsin and ATO
both induce an increase in ROS, but darinaparsin produces a
greater increase [4]. Darinaparsin is a potent inhibitor of
microtubule polymerization while the effects of ATO on
microtubules can vary. Some studies have reported that ATO
is a strong microtubule polymerizing agent that synergizes with
taxol, while others have shown ATO inhibition of the effects of
taxol [23,24,25]. Also, darinaparsin is effective in cells with
ATO-resistance [8,9]. Part of this latter difference may be due
to the ability of some multiple drug resistance transporters, such
as MRP1, to transport ATO out of cells [9]. In contrast, the
expression of MRP1 does not alter the effects or potency of
darinaparsin [8]. As noted previously for ATO [21], effective-
ness of darinaparsin is not altered in Mdr1-expressing cells. In
clinical trials, darinaparsin appears less toxic than ATO [6]. In
general, organic arsenicals, such as darinaparsin, are typically
less toxic than inorganic arsenicals, such as ATO [9]. The
lower toxicity of darinaparsin may seem a bit counterintuitive
given its broad range of activities, including strong action
against microtubule polymerization. Indeed, the differences in
practical therapeutic effects of darinaparsin may accrue from a
relative therapeutic index of multiple specific target activities
impacting neoplastic cells versus non-specific generalized effects
of arsenicals affecting mitochondrial functions [6]. In any case,
the range of actions of darinaparsin against multiple drivers of
neoplastic cells may make this organic arsenical an effective
therapy for multiple resistant solid and hematological malig-
nancies.
Methods
Cell Culture
HeLa cells (American Type Culture Collection, ATCC) were
maintained at 37uCi n5 %C O 2 using complete RPMI media
supplemented with 10% fetal bovine serum (FBS). Polyjet was used
for transfections according to the manufacturer’s protocol
(SignaGen). NIH 3T3 fibroblasts were maintained in high-glucose
Dulbecco’s modified Eagle’s (DMEM) medium supplemented with
10% FBS. To induce cilia formation, 3T3 cells were grown on
poly-L-lysine coated coverslips and maintained in DMEM
medium supplemented with 0.5% calf serum. ME-SA and ME-
SA/Dx5 cells (American Type Culture Collection, ATCC) were
maintained at 37uCi n5 %C O 2 using complete McCoy’s media
supplemented with 10% FBS.
Cell stress and recovery
For stress induction, HeLa cells were incubated at 37uC for
45 minutes (fixed cells) or 30 minutes (live cells) with a final
concentration of either 0.5 mM sodium arsenite (Riedel de Haen)
or 0.05 mM darinaparsin (Ziopharm). For microtubule depoly-
merization, cells were first incubated on ice for 30 minutes. Then,
cells were treated with 33 nM nocodazole (Calbiochem) for
90 minutes at 37uC. In recovery experiments, cells were washed
twice with serum-free media after treatment, and incubated in
complete RPMI media at 37uC for duration of recovery. For
primary cilia staining, 3T3 cells were treated with100 nM
Smoothened Agonist (SAG) [20], and with or without darinapar-
sin 18 hours before staining.
Fluorescence microscopy and analysis
For stress and recovery studies, HeLa cells grown on coverslips
were fixed at room temperature for 15 minutes using 4%
paraformaldehyde (PFA) supplemented with 0.1% Triton X-100,
80 mM K-PIPES pH 7.2, 1 mM EGTA, 1 mM MgSO4, and
30% glycerol. Cells were permeabilized with 0.25% Triton X-100
and blocked with 5% normal serum for one hour at room
temperature. The cells were incubated with primary antibodies for
one hour at room temperature: rabbit anti-AKAP350A (1:200),
rabbit anti-Caprin-1 (1:1000), mouse anti-a-tubulin (1:5000,
Sigma), rabbit anti-CCAR1 (1:1000), goat anti-GW182 (1:100,
Santa Cruz), and mouse anti-G3BP (1:800, BD Transduction).
This was followed by incubation at room temperature for one hour
with species-specific fluorescent secondary antibodies (1:500;
Invitrogen or Jackson Immunoresearch). Coverslips were mounted
using Prolong Gold with DAPI (Invitrogen). Cells were imaged
using a 606 oil immersion lens on Olympus FV-1000 confocal
fluorescence microscope (Vanderbilt Cell Imaging Shared Re-
source). The number and average size of granules in sodium
arsenite- and darinaparsin-treated cells were determined using
ImageJ software (NIH). At least ten cells were used per calculation.
Changes in granule number and size were analyzed using a
Student’s t-test. Changes in granule size over time in darinaparsin-
treated cells were analyzed using a one-way analysis of variance
(ANOVA) with post hoc examination of significant means using
Tukey’s test. Live-cell imaging was performed using a 606 oil
immersion lens on the DeltaVision Deconvolution microscope
(Vanderbilt Epithelial Biology Center Imaging Resource).
For primary cilia staining, 3T3 cells grown on coverslips were
fixed for 20 minutes in 4% paraformaldehyde and permeabilized
for 15 minutes in PBS with 0.3% Triton-X 100. The cells were
incubated in primary antibodies overnight at 4uC: rabbit-anti-
Arl13b (1:2000; gift from Tamara Caspary, Emery University) and
mouse-anti-a-tubulin (1:5000; Calbiochem). This was followed by
incubation at room temperature for one hour with species-specific
fluorescent secondary antibodies (1:1000; Invitrogen). DAPI was
included in the final washes before the samples were mounted in
Fluor Saver (Calbiochem) for microscopy. Images were taken with
Opti-Grid Confocal microscope. Cilia frequencies were deter-
mined from Arl13b/DAPI- stained cells from 6 samples per
treatment (15–30 cells per sample). Ciliary length was measured
using NIH ImageJ software. Bases and ends of immunolabeled
individual cilia were marked in the confocal z-stack images and
outlined, and the calculated length was recorded. P values were
calculated using unpaired t-test (GraphPad).
Microtubule polymerization
The effects of darinaparsin on microtubule polymerization were
assayed using a fluorescence-based polymerization assay (Cyto-
skeleton, Inc). Microtubule polymerization was initiated by GTP
A Multivalent Chemotherapeutic
PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27699or GTP/Taxol (1 mM) in the presence of increasing concentra-
tions of either darinaparsin (0.3 mM to 300 mM) or arsenite (1 mM
to 1 mM). Polymerization was monitored each minute by
fluorescence measurement for a total of one hour in a Biotek
Fluorescence plate reader.
Luciferase reporter assay
NIH3T3 cells were plated at 1.0610
5 cells/ml (24-well plate)
16 hours before transfection. Cells were co-transfected with 0.3 mg
8XGli1-luciferase reporter construct and 0.03 mg Renilla-lucifer-
ase control construct in each well. At 8 hours after transfection,
cells were fed low serum medium (0.5% calf serum + DMEM), and
then treated with Shh agonist (10 nM SAG) with or without
darinaparsin for an additional 20 hours. Luciferase assays were
performed with the Dual-Glo Luciferase System (Promega)
according to the manufacturer’s instructions. Each assay was
performed in triplicate and the results are presented as the relative
fold-increase (normalized to Renilla-luciferase activity) over non-
SAG-treated cells.
Supporting Information
Movie S1 Stress granules must complete formation before
dispersal. HeLa cells were transfected with pcherry-G3BP using
Effectene. Cells were treated with 0.05 mM darinaparsin for
30 minutes, washed with serum-free media twice, then incubated
in complete media for recovery.
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